PE13396A1 - Compuesto biciclico - Google Patents
Compuesto biciclicoInfo
- Publication number
- PE13396A1 PE13396A1 PE1995270715A PE27071595A PE13396A1 PE 13396 A1 PE13396 A1 PE 13396A1 PE 1995270715 A PE1995270715 A PE 1995270715A PE 27071595 A PE27071595 A PE 27071595A PE 13396 A1 PE13396 A1 PE 13396A1
- Authority
- PE
- Peru
- Prior art keywords
- bicycle compound
- bicycle
- compound
- formulawherein
- stress
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Controls And Circuits For Display Device (AREA)
- Projection Apparatus (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: A ES N o -CR6; B ES -NR1R2, -CR1R2R11, -NHCHR1R2, TETRAHIDROFURANILO ENTRE OTROS, DE PREFERENCIA LOS MENCIONADOS; R1 ES ALQUILO DE C1-C6 OPCIONALMENTE SUSTITUIDO POR OH, F, Cl ENTRE OTROS, DE PREFERENCIA ES ALQUILO DE C1-C4, SUSTITUIDOS CON OH y F; R2 ES ALQUILO DE C1-C12, ARILO,-(ALQUILENO C1-C4)ARILO, DONDE ARILO ES FENILO, NAFTILO ENTRE OTROS; DE PREFERENCIA BENCILO o ALQUILO DE C1-C6; R3 ES ALQUILO DE C1-C4, F, Br, I ENTRE OTROS, DE PREFERENCIA METILO Y CLORO; R4 ES HIDROGENO, ALQUILO C1-C6, F, Cl, Br; DE PREFERENCIA HIDROGENO, METILO Y ETILO; R5 ES FENILO, NAFTILO, TIENILO ENTRE OTROS Y PUEDEN ESTAR OPCIONALMENTE SUSTITUIDOS CON 2 o 3 SUSTITUYENTES TAL COMO F,Cl, FENILO ENTRE OTROS; R6 ES HIDROGENO, ALQUILO C1-C4, F, Cl, DE PREFRENCIA HIDROGENO, METILO, ETILO; R7 ES H, ALQUILO C1-C4, F; R11 ES H, F, OH, DE PREFERENCIA LAS DOS PRIMERAS; R12 ES H o ALQUILO C1-C4. SE CARACTERIZA POR ANTAGONIZAR EL CRF, EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y GASTROINTESTINALES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26005594A | 1994-06-16 | 1994-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE13396A1 true PE13396A1 (es) | 1996-04-27 |
Family
ID=22987613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1995270715A PE13396A1 (es) | 1994-06-16 | 1995-06-08 | Compuesto biciclico |
Country Status (27)
Country | Link |
---|---|
US (1) | US6248753B1 (es) |
EP (1) | EP0765327B1 (es) |
JP (1) | JP2891544B2 (es) |
KR (1) | KR100235277B1 (es) |
CN (1) | CN1056611C (es) |
AT (1) | ATE182332T1 (es) |
AU (1) | AU687196B2 (es) |
BR (1) | BR9502707A (es) |
CA (1) | CA2192820C (es) |
CO (1) | CO4290424A1 (es) |
CZ (1) | CZ287613B6 (es) |
DE (1) | DE69510940T2 (es) |
DK (1) | DK0765327T3 (es) |
ES (1) | ES2135062T3 (es) |
FI (1) | FI112659B (es) |
GR (1) | GR3031166T3 (es) |
HU (1) | HU219911B (es) |
IL (1) | IL114003A (es) |
MX (1) | MX9606504A (es) |
NO (1) | NO307968B1 (es) |
NZ (1) | NZ284846A (es) |
PE (1) | PE13396A1 (es) |
PL (1) | PL181895B1 (es) |
RU (1) | RU2135498C1 (es) |
TW (1) | TW432064B (es) |
WO (1) | WO1995034563A1 (es) |
ZA (1) | ZA954679B (es) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
AU738304B2 (en) * | 1995-10-13 | 2001-09-13 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands |
US6992188B1 (en) | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
JP2000507552A (ja) * | 1996-03-26 | 2000-06-20 | デュポン ファーマシューティカルズ カンパニー | アリールオキシおよびアリールチオ縮合ピリジン、アリールオキシおよびアリールチオ縮合ピリミジン、およびそれらの誘導体 |
ZA972497B (en) | 1996-03-27 | 1998-09-25 | Du Pont Merck Pharma | Arylamino fused pyridines and pyrimidines |
US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
US6060478A (en) * | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
US7094782B1 (en) | 1996-07-24 | 2006-08-22 | Bristol-Myers Squibb Company | Azolo triazines and pyrimidines |
US6124289A (en) | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
JP3345021B2 (ja) * | 1996-08-06 | 2002-11-18 | ファイザー インク. | 置換ピリド―またはピリミド―含有6,6―または6,7―二環式誘導体 |
TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
AU4270297A (en) | 1996-09-16 | 1998-04-02 | Du Pont Pharmaceuticals Company | Pyrazinones and triazinones and their derivatives thereof |
JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crfレセプターアンタゴニストおよびそれらに関連する方法 |
NZ502642A (en) | 1997-07-03 | 2002-06-28 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
EP1012151B1 (en) | 1997-09-02 | 2002-08-07 | Bristol-Myers Squibb Pharma Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
NL1010018C2 (nl) * | 1997-09-09 | 1999-03-10 | Duphar Int Res | Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking. |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
EP1068206A1 (en) * | 1998-04-02 | 2001-01-17 | Neurogen Corporation | Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
JP2002510686A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキルで置換された5,6,7,8−テトラヒドロ−9H−ピリジノ[2,3−b]インドール及び5,6,7,8−テトラヒドロ−9Hピリミジノ[4,5−B]インドール誘導体:CRF1特異的配位子 |
US6472402B1 (en) | 1998-04-02 | 2002-10-29 | Neurogen Corporation | Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
DE19837387A1 (de) * | 1998-08-18 | 2000-02-24 | Aventis Res & Tech Gmbh & Co | 3'-Desoxypentopyranosyl-Nucleinsäure, ihre Herstellung und Verwendung |
US6174912B1 (en) | 1998-08-21 | 2001-01-16 | Dupont Pharmaceuticals Company | Nitrogen substituted imidazo[4,5-C]pyrazoles as corticotropin releasing hormone antagonists |
CA2349904A1 (en) | 1998-11-12 | 2000-05-18 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods relating thereto |
DK1129091T3 (da) * | 1998-11-12 | 2002-11-04 | Neurocrine Biosciences Inc | Antagonister for CRF-receptorer og fremgangsmåder med relation dertil |
US6531475B1 (en) | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
US6271380B1 (en) | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
US6387894B1 (en) | 1999-06-11 | 2002-05-14 | Pfizer Inc. | Use of CRF antagonists and renin-angiotensin system inhibitors |
US6432989B1 (en) | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
CA2379640C (en) | 1999-09-30 | 2006-11-28 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
IL139197A0 (en) * | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
JP2003516992A (ja) * | 1999-12-17 | 2003-05-20 | デュポン ファーマシューティカルズ カンパニー | イミダゾピリミジニル誘導体およびイミダゾピリジニル誘導体 |
AU2001232271A1 (en) * | 2000-02-14 | 2001-08-20 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
ATE287886T1 (de) | 2000-04-25 | 2005-02-15 | Bristol Myers Squibb Co | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer |
US6630476B2 (en) | 2000-07-07 | 2003-10-07 | Bristol-Myers Squibb Pharma Company | Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists |
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
DE10042093A1 (de) * | 2000-08-26 | 2002-03-07 | Dresden Arzneimittel | Antikonvulsiv wirkende 6,7-Dihydro-pyrrolo[3,4-d]pyridin-5-one und Verfahren zu deren Darstellung |
CA2422054C (en) | 2000-09-22 | 2011-01-11 | Akzo Nobel Nv | Bicyclic heteroaromatic compounds |
TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
BR0209252A (pt) | 2001-04-27 | 2004-07-20 | Eisai Co Ltd | Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas |
GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
GB0128287D0 (en) * | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
CA2468927A1 (en) * | 2001-12-04 | 2003-06-12 | F. Hoffmann-La Roche Ag | Ring fused pyrazole derivatives |
ATE457312T1 (de) * | 2002-03-28 | 2010-02-15 | Eisai R&D Man Co Ltd | Azaindole als hemmstoffe von c-jun n-terminalen kinasen |
GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
DE60326869D1 (de) | 2002-10-22 | 2009-05-07 | Eisai R&D Man Co Ltd | 7-phenylpyrazolopyridinverbindungen |
US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
TWI270549B (en) | 2002-12-26 | 2007-01-11 | Taisho Pharmaceutical Co Ltd | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
MY144903A (en) * | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
EP1802621B1 (en) | 2004-10-19 | 2009-05-06 | SmithKline Beecham (Cork) Limited | Crf receptor antagonists and methods relating thereto |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
GB0525143D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
GB0525337D0 (en) * | 2005-12-13 | 2006-01-18 | Novartis Ag | Organic compounds |
JP2009529047A (ja) | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
BRPI0710527B8 (pt) * | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
PT2266990E (pt) | 2008-04-15 | 2012-12-27 | Eisai R&D Man Co Ltd | Composto de 3-fenilpirazolo[5,1-b]tiazole |
WO2009143992A1 (de) | 2008-05-29 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
AR078521A1 (es) | 2009-10-08 | 2011-11-16 | Eisai R&D Man Co Ltd | Compuesto pirazolotiazol |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
WO2012158913A2 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9676779B2 (en) | 2012-11-20 | 2017-06-13 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
AU2013348019A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule bicyclic and tricyclic CFTR correctors |
TWI498325B (zh) | 2013-01-18 | 2015-09-01 | Hoffmann La Roche | 3-取代吡唑及其用途 |
CN108558876B (zh) * | 2018-05-28 | 2020-08-04 | 中南大学 | 吡唑[3,4-b]并吡啶类衍生物及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3925388A (en) * | 1971-08-05 | 1975-12-09 | Squibb & Sons Inc | 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters |
US3804843A (en) * | 1971-12-23 | 1974-04-16 | Squibb & Sons Inc | Amino derivatives of pyrazolopyridine carbonitriles |
DE3145287A1 (de) | 1981-11-14 | 1983-05-19 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
IT1154024B (it) * | 1982-09-22 | 1987-01-21 | Lepetit Spa | Derivati pridinici e procedimento per la loro produzione |
US4605642A (en) | 1984-02-23 | 1986-08-12 | The Salk Institute For Biological Studies | CRF antagonists |
US5063245A (en) | 1990-03-28 | 1991-11-05 | Nova Pharmaceutical Corporation | Corticotropin-releasing factor antagonism compounds |
JPH05196008A (ja) | 1991-11-20 | 1993-08-06 | Myotoku Kk | 空気圧動作装置とその制御装置 |
WO1993010715A2 (en) | 1991-12-03 | 1993-06-10 | Vesitec Medical, Inc. | Surgical treatment of stress urinary incontinence |
IT222061Z2 (it) | 1991-12-03 | 1994-12-29 | Hydro Aluminium Systems Spa | Complesso di profilati metallici per serramenti muniti di squadrette di rinforzo |
JPH0669494B2 (ja) | 1991-12-04 | 1994-09-07 | 南雄 河野 | 医療用窓付断熱カテーテル |
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
PL176526B1 (pl) * | 1992-12-17 | 1999-06-30 | Pfizer | Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę |
WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
-
1995
- 1995-05-18 DK DK95917436T patent/DK0765327T3/da active
- 1995-05-18 PL PL95317705A patent/PL181895B1/pl not_active IP Right Cessation
- 1995-05-18 ES ES95917436T patent/ES2135062T3/es not_active Expired - Lifetime
- 1995-05-18 MX MX9606504A patent/MX9606504A/es not_active IP Right Cessation
- 1995-05-18 HU HU9603469A patent/HU219911B/hu not_active IP Right Cessation
- 1995-05-18 CA CA002192820A patent/CA2192820C/en not_active Expired - Fee Related
- 1995-05-18 CZ CZ19963670A patent/CZ287613B6/cs not_active IP Right Cessation
- 1995-05-18 CN CN95193638A patent/CN1056611C/zh not_active Expired - Fee Related
- 1995-05-18 DE DE69510940T patent/DE69510940T2/de not_active Expired - Fee Related
- 1995-05-18 KR KR1019960707183A patent/KR100235277B1/ko not_active IP Right Cessation
- 1995-05-18 NZ NZ284846A patent/NZ284846A/xx unknown
- 1995-05-18 RU RU96123712/04A patent/RU2135498C1/ru not_active IP Right Cessation
- 1995-05-18 WO PCT/IB1995/000373 patent/WO1995034563A1/en active IP Right Grant
- 1995-05-18 JP JP8501868A patent/JP2891544B2/ja not_active Expired - Fee Related
- 1995-05-18 AT AT95917436T patent/ATE182332T1/de not_active IP Right Cessation
- 1995-05-18 AU AU23505/95A patent/AU687196B2/en not_active Ceased
- 1995-05-18 EP EP95917436A patent/EP0765327B1/en not_active Expired - Lifetime
- 1995-05-25 TW TW084105306A patent/TW432064B/zh active
- 1995-06-05 IL IL11400395A patent/IL114003A/xx not_active IP Right Cessation
- 1995-06-07 ZA ZA954679A patent/ZA954679B/xx unknown
- 1995-06-07 BR BR9502707A patent/BR9502707A/pt not_active IP Right Cessation
- 1995-06-08 CO CO95024908A patent/CO4290424A1/es unknown
- 1995-06-08 PE PE1995270715A patent/PE13396A1/es not_active Application Discontinuation
-
1996
- 1996-12-13 NO NO965378A patent/NO307968B1/no not_active IP Right Cessation
- 1996-12-13 FI FI965022A patent/FI112659B/fi active
-
1999
- 1999-03-11 US US09/266,353 patent/US6248753B1/en not_active Expired - Fee Related
- 1999-09-08 GR GR990402259T patent/GR3031166T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE13396A1 (es) | Compuesto biciclico | |
DE69603240T2 (de) | Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden | |
FI935585A0 (fi) | Pyrrolopyrimidiner | |
SE9801494D0 (sv) | Novel use | |
CY1107039T1 (el) | Αναστολεις τριπεπτιδυλ πεπτιδασης | |
BR0314139A (pt) | Derivados de 1,4-pirazina substituìdos | |
ATE317263T1 (de) | Diphosphonat derivate von therapeutisch wirksamen stoffen | |
ID26405A (id) | Pemurnian karboksaldehida | |
ID27733A (id) | Metoksiminofenilasetamida | |
DE69601154D1 (de) | Zubereitungen für die Behandlung von Hepatitis C | |
ATE242224T1 (de) | Fungizide aza-heterocycloalkene | |
BR9611904A (pt) | Dioxidos de ditiazol | |
ATE212839T1 (de) | Hämoregulatorische verbindungen | |
ES2060162T3 (es) | Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina. | |
NL1001157A1 (nl) | Zuiveringsinstallatie. | |
KR970016336U (ko) | 오,폐수처리장의 탈취장치 | |
FR2692483B1 (fr) | Masques dermiques énergétiques. | |
MA23295A1 (fr) | Calendrier des siecles. | |
ECSP951463A (es) | Compuestos biciclicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |